ArticleBritish journal of clinical pharmacology2026
Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients.British journal of clinical pharmacology · 2026Article
- Toxic epidermal necrolysis and acute kidney injury following co-trimoxazole rechallenge and voriconazole accumulation as an exacerbating cofactor: a case report.Frontiers in toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsVoriconazole is commonly used to prevent fungal infections after haematopoietic stem cell transplantation (HSCT). Although its metabolism is influenced by CYP2C19 genetics and inflammation, their combined effect is rarely considered in clinical practice, and integrated analyses remain limited.
methodsWe retrospectively analysed how inflammation and CYP2C19-predicted drug-metaboliser phenotypes affect voriconazole exposure and therapeutic range attainment in 126 HSCT patients. C-reactive protein (CRP) ≥ 10 mg/L defined inflammation. A linear mixed model (LMM) assessed associations between dose-corrected voriconazole concentrations, inflammation and CYP2C19-predicted drug-metaboliser phenotype.
resultsDose-corrected voriconazole trough concentrations were associated with CYP2C19-predicted drug-metaboliser phenotype (LMM p = <2e-16, effect size of CYP2C19-phenotype: β = -5.99e-02-mg/L per mg voriconazole, standard error (SE) = 2.75e-02-mg/L per mg voriconazole, p = 0.0315; effect size of CRP: β = 1.54e-03-mg/L per mg voriconazole, SE = 2.79E-04-mg/L per mg voriconazole, p = 5.49e-08) and were higher during inflammation. Inflammation increased supra-therapeutic concentrations and reduced subtherapeutic levels (p = 0.0080). This effect was most pronounced for intermediate metabolisers (n = 18 with and n = 31 without inflammation) and rapid metabolisers (n = 20 with and n = 28 without inflammation), with supra-therapeutic concentration of 33% vs. 3%, and 15% vs. 0%, respectively (p = 0.02). Finally, in a longitudinal subset (n = 25), concentrations tracked inflammatory status across prior-, during and post-inflammation timepoints.
conclusionsThis study demonstrates inflammation and CYP2C19 genotype jointly influence voriconazole exposure and target attainment in clinical practice. These findings support intensified therapeutic drug monitoring with concurrent CRP assessment, particularly for intermediate and rapid metabolisers, to reduce the risk of supra-therapeutic voriconazole concentrations during inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.